Novo Nordisk A/S $NVO Stake Lifted by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 134.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 164,673 shares of the company’s stock after acquiring an additional 94,513 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Novo Nordisk A/S were worth $6,243,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Novo Nordisk A/S by 2,414.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after buying an additional 286,034 shares during the last quarter. Trust Co. of Vermont bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $1,250,000. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $2,324,000. Myriad Asset Management Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $1,846,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Novo Nordisk A/S by 22.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company’s stock valued at $11,007,000 after buying an additional 42,361 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Third-quarter results beat expectations: adjusted sales were DKK 79.2 billion, obesity sales grew 22%, and adjusted operating profit increased 27%. Novo raised its full-year 2026 outlook, citing demand for its GLP-1 portfolio. Reuters: Novo Nordisk Q3 profit beats forecast; raises 2026 guidance
• Positive Sentiment: Wegovy pill adoption exceeded management’s expectations and came in ahead of forecasts, bolstering the growth outlook. Novo plans to expand the pill into more than 20 markets by mid-2027. BioPharma Dive: Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
• Positive Sentiment: Novo and Abbott are expanding their diabetes-drug collaboration in Asia, potentially supporting wider regional reach. MarketScreener: Abbott and Novo Nordisk expand collaboration on diabetes drug in Asia
• Neutral Sentiment: The company did not provide 2027 guidance. Management cited factors that could help or hinder next year’s sales, leaving investors without a firm near-term growth target. The Motley Fool: Novo Nordisk Stock Jumped After Earnings — But Its CEO Won’t Give 2027 Guidance
• Negative Sentiment: Despite solid sales, coverage highlights a squeeze on profits, while impairment charges weighed on reported operating profit. Pricing pressure and questions about future margins may be tempering enthusiasm for the outlook. Yahoo Finance: Novo Nordisk Stock Faces Q3 Earnings Profit Squeeze
• Negative Sentiment: CFO Karsten Munk Knudsen is leaving the company. The upcoming handover adds a management transition as investors assess the earnings and outlook. Reuters: Novo Nordisk’s CFO Karsten Munk Knudsen to leave company

Novo Nordisk A/S Trading Down 4.5%

Shares of NVO stock opened at $40.29 on Friday. The company’s fifty day simple moving average is $40.70 and its two-hundred day simple moving average is $43.96. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The stock has a market capitalization of $179.89 billion, a price-to-earnings ratio of 10.15, a PEG ratio of 1.42 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 54.22% and a net margin of 33.99%. The firm had revenue of $11.98 billion for the quarter. As a group, analysts anticipate that Novo Nordisk A/S will post 3.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. BMO Capital Markets set a $40.00 price target on Novo Nordisk A/S and gave the stock a “market perform” rating in a research note on Monday, October 12th. Berenberg Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Barclays restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Cfra downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective on the stock. in a report on Tuesday, September 22nd. Finally, HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $59.44.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.